Emrelis (telisotuzumab vedotin-tllv) [package insert]. FDA.

Regulatory approval published by the Food and Drug Administration.

Citation

Abbvie Inc. Emrelis (telisotuzumab vedotin-tllv) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf. Revised May 2025. Accessed June 12, 2025.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	c-Met >= 50%	Lung Non-Squamous Non-Small Cell Carcinoma	Telisotuzumab Vedotin